CCR2/CCR5 antagonist (Bristol-Myers Squibb Co)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameCCR2/CCR5 antagonist (Bristol-Myers Squibb Co)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 5 antagonistsC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 5C-C chemokine receptor type 2
Therapy Area/IndicationsMetabolic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsMetabolic Diseases

Other Information

ATC CodeN/A
Related LinksN/A